DLL4

Results: 11



#Item
1Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

Targeting Notch/Delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF) pathways by an anti-DLL4/Anti-VEGF bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency in

Add to Reading List

Source URL: posters.omed.s3.amazonaws.com

- Date: 2015-06-12 10:36:45
    2Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

    Preclinical and Clinical Activity of Anti-DLL4 (Demcizumab) in Combination with Gemcitabine Plus nab-Paclitaxel in Pancreatic Cancer Manuel Hidalgo*, Antonio Cubillo*, Robert Stagg**, Jakob Dupont**, Wan-Ching Yen**, Tim

    Add to Reading List

    Source URL: s3.amazonaws.com

    - Date: 2014-11-19 14:29:44
      3Dual targeting of delta-like ligand 4 (DLL4) and programmed death 1 (PD1) inhibits tumor growth and generates enhanced long-term immunological memory. Minu K. Srivastava, Christopher L. Murriel, Julie Roda, Hyun-Bae Jie,

      Dual targeting of delta-like ligand 4 (DLL4) and programmed death 1 (PD1) inhibits tumor growth and generates enhanced long-term immunological memory. Minu K. Srivastava, Christopher L. Murriel, Julie Roda, Hyun-Bae Jie,

      Add to Reading List

      Source URL: posters.omed.s3.amazonaws.com

      - Date: 2015-06-12 10:40:55
        4A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

        A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer Dose Level – mg/kg Median age (years)

        Add to Reading List

        Source URL: posters.omed.s3.amazonaws.com

        - Date: 2016-01-22 10:42:40
          5A First-in-Man Phase 1a Study of the Bispecific Anti-DLL4/Anti-VEGF Antibody OMP-305B83 in Patients with Previously Treated Solid Tumors Jimeno A1, Moore K2, Gordon M3, Chugh R4, Diamond J1, Aljumaily R2, Stagg R5, Dupon

          A First-in-Man Phase 1a Study of the Bispecific Anti-DLL4/Anti-VEGF Antibody OMP-305B83 in Patients with Previously Treated Solid Tumors Jimeno A1, Moore K2, Gordon M3, Chugh R4, Diamond J1, Aljumaily R2, Stagg R5, Dupon

          Add to Reading List

          Source URL: publications.oncomed.com

          - Date: 2016-11-29 01:36:20
            6A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

            A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM, anti-DLL4) and Gemcitabine (GEM) with or without Nab-Paclitaxel in Patients with Pancreatic Cancer 1Hidalgo Patient Demographics (n=47) DEM + GEM

            Add to Reading List

            Source URL: s3.amazonaws.com

            - Date: 2014-09-25 16:14:56
              7Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

              Dual targeting of the DLL4 and VEGF pathways with a bi-specific monoclonal antibody inhibits tumor growth and reduces cancer stem cell frequency Wan-Ching Yen, Marcus M. Fischer, Gretchen Argast, Breanna Wallace, Min Wan

              Add to Reading List

              Source URL: posters.omed.s3.amazonaws.com

              - Date: 2015-11-04 11:34:26
                8Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Minu K. Srivastava, Chr

                Co-Targeting of Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF) with Programmed Death 1 (PD1) blockade inhibits tumor growth and facilitates anti-tumor immune responses. Minu K. Srivastava, Chr

                Add to Reading List

                Source URL: posters.omed.s3.amazonaws.com

                - Date: 2015-11-04 13:26:51
                  9Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors Alayne Brunner, Fiore Cattaruzza, Wan-Ching Yen, Pete Yeung, Marcus Fischer, Belinda Cancilla, Christopher L. Murriel, Gilbert O

                  Effects of anti-DLL4 treatment on non-small cell lung cancer (NSCLC) human xenograft tumors Alayne Brunner, Fiore Cattaruzza, Wan-Ching Yen, Pete Yeung, Marcus Fischer, Belinda Cancilla, Christopher L. Murriel, Gilbert O

                  Add to Reading List

                  Source URL: posters.omed.s3.amazonaws.com

                  - Date: 2016-04-20 00:02:44
                    10Supplementary figure 1 Schematic representation of DLL4 locus in Homo sapiens chromosome 15, GRCh38 Primary Assembly. DLL4 mRNA starting fromis shown in red boxes; DLL4-AS starting fromand ending at 4

                    Supplementary figure 1 Schematic representation of DLL4 locus in Homo sapiens chromosome 15, GRCh38 Primary Assembly. DLL4 mRNA starting fromis shown in red boxes; DLL4-AS starting fromand ending at 4

                    Add to Reading List

                    Source URL: vascularcell.com

                    Language: English